ACTA1 and facioscapulohumeral muscular dystrophy: Importantly, we characterized ACTA1-MCM;FLExDUX4 mice, with and without TMX, as valuable new tools for FSHD research and for pre-clinical testing of potential FSHD therapeutics targeting DUX4-fl mRNA, protein, and certain downstream effects.